OBJECTIVES: To assess the efficacy of two treatment options for non-muscle-invasive bladder cancer (NMIBC): (1) transurethral resection (TUR) guided by fluorescence cystoscopy (FC) with the use of 5-aminolevulinic acid (5-ALA) and (2) single early instillation of doxorubicin in a single-center open-label prospective randomized study with a 2 × 2 factorial design. PATIENTS AND METHODS: Patients with clinical suspicion of primary or recurrent NMIBC were randomized into four study arms: FC-assisted TUR with 5-ALA and single instillation of doxorubicin, FC-assisted TUR without instillation, TUR in white light (WL) with single instillation of doxorubicin, and WL-TUR only. The study was designed to assess recurrence-free survival in arms with and without any of two interventions. RESULTS:Of 525 patients included, 377 (72 %) were eligible for primary outcome assessment. The median follow-up was 54.8 months. FC statistically significantly decreased the risk of disease recurrence and progression with hazard ratio (HR) 0.56 (95 % CI 0.39-0.80, p = 0.001) and 0.33 (95 % CI 0.12-0.91, p = 0.031), respectively. The HRs for recurrence and progression for single instillation of doxorubicin were 0.76 (95 % CI 0.54-1.07, p = 0.11) and 0.65 (95 % CI 0.28-1.52, p = 0.32), respectively. The overall and cancer-specific survival rates did not differ significantly based on the therapeutic interventions. CONCLUSIONS: In patients with NMIBC, FC-assisted TUR with 5-ALA results in a substantial recurrence and progression risk reduction as compared to WL-TUR. The single early postoperative instillation of doxorubicin did not have a statistically significant impact on recurrence and progression risks.
RCT Entities:
OBJECTIVES: To assess the efficacy of two treatment options for non-muscle-invasive bladder cancer (NMIBC): (1) transurethral resection (TUR) guided by fluorescence cystoscopy (FC) with the use of 5-aminolevulinic acid (5-ALA) and (2) single early instillation of doxorubicin in a single-center open-label prospective randomized study with a 2 × 2 factorial design. PATIENTS AND METHODS: Patients with clinical suspicion of primary or recurrent NMIBC were randomized into four study arms: FC-assisted TUR with 5-ALA and single instillation of doxorubicin, FC-assisted TUR without instillation, TUR in white light (WL) with single instillation of doxorubicin, and WL-TUR only. The study was designed to assess recurrence-free survival in arms with and without any of two interventions. RESULTS: Of 525 patients included, 377 (72 %) were eligible for primary outcome assessment. The median follow-up was 54.8 months. FC statistically significantly decreased the risk of disease recurrence and progression with hazard ratio (HR) 0.56 (95 % CI 0.39-0.80, p = 0.001) and 0.33 (95 % CI 0.12-0.91, p = 0.031), respectively. The HRs for recurrence and progression for single instillation of doxorubicin were 0.76 (95 % CI 0.54-1.07, p = 0.11) and 0.65 (95 % CI 0.28-1.52, p = 0.32), respectively. The overall and cancer-specific survival rates did not differ significantly based on the therapeutic interventions. CONCLUSIONS: In patients with NMIBC, FC-assisted TUR with 5-ALA results in a substantial recurrence and progression risk reduction as compared to WL-TUR. The single early postoperative instillation of doxorubicin did not have a statistically significant impact on recurrence and progression risks.
Entities:
Keywords:
5-Aminolevulinic acid; Fluorescence cystoscopy; Non-muscle-invasive bladder cancer; Single early instillation of chemotherapeutic drug
Authors: Dmitry I Daniltchenko; Claus R Riedl; Markus D Sachs; Frank Koenig; Kurosch L Daha; Heinz Pflueger; Stefan A Loening; Dietmar Schnorr Journal: J Urol Date: 2005-12 Impact factor: 7.450
Authors: Arnulf Stenzl; Hannes Penkoff; Elfriede Dajc-Sommerer; Andreas Zumbraegel; Lorenz Hoeltl; Michael Scholz; Claus Riedl; Josef Bugelnig; Alfred Hobisch; Maximilian Burger; Gregor Mikuz; Uwe Pichlmeier Journal: Cancer Date: 2010-11-08 Impact factor: 6.860
Authors: Richard J Sylvester; Adrian P M van der Meijden; Willem Oosterlinck; J Alfred Witjes; Christian Bouffioux; Louis Denis; Donald W W Newling; Karlheinz Kurth Journal: Eur Urol Date: 2006-01-17 Impact factor: 20.096
Authors: Maurizio Brausi; Laurence Collette; Karlheinz Kurth; Adrian P van der Meijden; Wim Oosterlinck; J A Witjes; Donald Newling; Christian Bouffioux; Richard J Sylvester Journal: Eur Urol Date: 2002-05 Impact factor: 20.096
Authors: Stefan Denzinger; Maximilian Burger; Bernhard Walter; Ruth Knuechel; Wolfgang Roessler; Wolf F Wieland; Thomas Filbeck Journal: Urology Date: 2007-04 Impact factor: 2.649
Authors: Martin C Schumacher; Sten Holmäng; Thomas Davidsson; Bengt Friedrich; Jörgen Pedersen; N Peter Wiklund Journal: Eur Urol Date: 2009-11-06 Impact factor: 20.096
Authors: Graham Mowatt; James N'Dow; Luke Vale; Ghulam Nabi; Charles Boachie; Jonathan A Cook; Cynthia Fraser; T R Leyshon Griffiths Journal: Int J Technol Assess Health Care Date: 2011-01-25 Impact factor: 2.188
Authors: C A Chai; W S Yeoh; R Rajandram; K P Aung; T A Ong; S Kuppusamy; A Nazran; K Kumaran; A H A Razack; J Y Teoh Journal: Front Surg Date: 2021-05-13
Authors: Britta Grüne; Jan Rother; Frank Waldbillig; Ganapathy Chellappan; Sabine Meessen; Bartłomiej Grychtol; Nikolaos C Deliolanis; Christian Bolenz; Maximilian C Kriegmair Journal: Transl Androl Urol Date: 2021-06